Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $4.62M |
| Gross Profit (TTM) | $-22.57M |
| EBITDA | $-50.03M |
| Operating Margin | 1192.00% |
| Return on Equity | 0.00% |
| Return on Assets | -22.50% |
| Revenue/Share (TTM) | $1.14 |
| Book Value | $-7.45 |
| Price-to-Book | 80.40 |
| Price-to-Sales (TTM) | 7.50 |
| EV/Revenue | 18.36 |
| EV/EBITDA | 44.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.50% |
| Shares Outstanding | $4.05M |
| Float | $3.56M |
| % Insiders | 2.02% |
| % Institutions | 24.68% |
Volatility is currently expanding
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment.
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company's recent developments.
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KYNB and any ticker you trade — then tracks every position and per-strategy win rate.
